Before 2033, will semaglutide be shown to improve lifespan, when prescribed to overweight people?
10
66
210
2033
75%
chance

We'll check Google Scholar in 2033-Jan, and see how the long-term mortality data is looking for overweight people prescribed semaglutide. Must be significant at p<0.005. "Semaglutide" also refers to the brand names Ozempic, Wegovy and Rybelsus, etc.

Will semaglutide be shown to improve lifespan, when prescribed to overweight people?

Get Ṁ1,000 play money
Sort by:
bought Ṁ50 of NO

Absolutely not. For starters, we don't even know for certain if being overweight increases risk of mortality to any substantial degree, except in the morbidly obese. Second of all, wegovy is a very blunt tool as a drug. It induces weight loss by greatly decreasing appetite, but robust appetite is often a heuristic for good health and appetite signalling can be useful in helping people auto adjust to changing health circumstances like illnesses (temporary, chronic, and terminal) and maintaining virility. Then there's the whole issue of wegovy negatively affecting insulin sensitivity by causing the pancreas to secrete excess insulin. Poor insulin sensitivity is one of the strongest indicators of good health and longevity--much better than weight for that matter. And there's really not much evidence to suggest that non-morbidly obese people who lose weight and become normal weight have significantly better mortality rates than non morbidly obese overweight people who don't.

Fixed up the close and resolution dates, they were a bit unclear.